
MorphoSys AG MOR
Annual report 2023
added 12-27-2025
MorphoSys AG Long Term Debt Current 2011-2026 | MOR
Annual Long Term Debt Current MorphoSys AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.63 M | 7.56 M | 3.24 M | 3.06 M | 2.03 M | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.56 M | 2.03 M | 3.9 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Heron Therapeutics
HRTX
|
3.04 M | $ 0.79 | 1.9 % | $ 132 M | ||
|
Altimmune
ALT
|
256 K | $ 3.44 | 2.99 % | $ 303 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 218.03 | -1.74 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Incyte Corporation
INCY
|
5.7 M | $ 90.43 | -0.21 % | $ 17.7 B | ||
|
Inovio Pharmaceuticals
INO
|
2.41 M | $ 1.54 | -2.41 % | $ 34.1 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
780 K | $ 13.57 | 7.1 % | $ 818 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
KalVista Pharmaceuticals
KALV
|
1.98 M | $ 16.82 | -1.06 % | $ 835 M | ||
|
Kamada Ltd.
KMDA
|
2.12 M | $ 8.27 | 0.24 % | $ 260 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
768 K | $ 2.13 | 1.67 % | $ 199 M | ||
|
Karyopharm Therapeutics
KPTI
|
438 K | $ 7.11 | -6.82 % | $ 866 K | ||
|
Denali Therapeutics
DNLI
|
8.31 M | $ 20.99 | 4.07 % | $ 3.45 B | ||
|
Keros Therapeutics
KROS
|
2.41 M | $ 11.16 | 1.82 % | $ 415 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.35 | 2.48 % | $ 722 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M |